

Centrum Medyczne ENEL-MED S.A. Capital Group

Management Board's Report on
activity in the 1st half of 2015

Warsaw, 27 August 2015



CENTRUM MEDYCZNE


Table of contents

1. BASIC INFORMATION ABOUT CENTRUM MEDYCZNE ENEL-MED S.A. CAPITAL GROUP	3
1.1. The structure of Capital Group	3
1.2. Effects of changes in the structure of the business entity.....	4
1.3. Management Board and Supervisory Board.....	4
1.4. Shareholding structure	5
1.5. The activity of Centrum Medyczne ENEL-MED S.A. and its Capital Group	6
2. MAJOR EVENTS OF THE 1ST HALF OF 2015.....	7
3. OTHER INFORMATION.....	8
3.1. Principles of drawing up interim condensed financial statements.....	8
3.2. Basic threats and risks associated with the remaining months of the financial year	8
3.3. The Management Board's position on the feasibility of the previously published forecasts for the year	13
3.4. Information regarding shareholders holding at least 5% of the total number of votes at the general meeting of shareholders, directly or indirectly through subsidiaries	13
3.5. Information on the Issuer's shares held by members of the management and supervisory authorities	13
3.6. Information on pending proceedings before courts, arbitration bodies or public administration bodies with regard to liabilities or receivables	14
3.7. Information on the Issuer or its subsidiary granting a surety for credits or loans, or granting a guarantee if their total value is equal to at least 10% of the Issuer's equity.....	14
3.8. Information on the Issuer or its subsidiary entering into one or more transactions with related parties if individually or jointly they are significant and have been concluded on non-arm's length conditions	15
3.9. Information on factors that, in the Company's view, will affect its results from the perspective of at least the next quarter	15
3.10. Other information that could significantly affect the evaluation of assets, financial condition and financial result of the Issuer.....	15
3.11. Other information which in the Issuer's opinion is important for the evaluation of its personnel, assets and financial condition, financial result and changes therein, as well as information vital for the evaluation of the Issuer's capacity to perform its obligations.....	15

1. BASIC INFORMATION ON CENTRUM MEDYCZNE ENEL-MED S.A. CAPITAL GROUP

1.1. The structure of Capital Group

Centrum Medyczne ENEL-MED S.A. (hereinafter referred to also as ENEL-MED or the Company) is a part of Capital Group which as of 30 June 2015 is comprised of Centrum Medyczne ENEL-MED S.A. as the parent company and its subsidiaries: Enelbud sp. z o.o., Enel Invest sp. z o.o., and Pro Care sp. z o.o. as well as the associated Bonus Vitae sp. z o.o.



Enelbud sp. z o.o. - a company established in 2006, engaged in real property investments in the healthcare sector. The parent company Centrum Medyczne ENEL-MED S.A. as of 30 June 2015 held 80 shares in this subsidiary, which accounted for 80% of the subsidiary's share capital. As of the publication of this report Centrum Medyczne ENEL-MED S.A. holds 100 shares, representing 100% of the subsidiary's share capital.

Enel Invest sp. z o.o. - a company established in the fourth quarter of 2013 in which Centrum Medyczne ENEL-MED S.A. holds 510,000 shares, representing 100% of the share capital. On 10 April 2015, the business name of Centrum Medyczne Diagnostyka Obrazowa sp. z o.o. was changed to Enel Invest sp. z o.o. The main asset of Enel Invest sp. z o.o. is the funds from which the Issuer shall finance development of the Capital Group.

Pro Care sp. z o.o. - a company established in the second quarter of 2015 in which Enel Invest sp. z o.o. holds 49 shares, representing 98% of the share capital. The core operational activity of Pro Care is associated with long-term medical care facilities.

Bonus Vitae sp. z o.o. - a company in which Enelbud sp. z o.o. holds a 40% share. The planned business activity is long-term medical care for the elderly.

As of 30 June 2015, the Issuer consolidated the following companies: Enelbud sp. z o.o. and Enel Invest sp. z o.o. using the full method and Bonus Vitae sp. z o.o. using the equity method.

Due to the immateriality of the financial data, Pro Care sp. z o.o. as of 30 June 2015 has not been consolidated.

1.2. Effects of changes in the structure of the business entity

Following the establishment of the company under the name Pro Care sp. z o.o. and the acquisition of 98% of the shares in its share capital by Enel Invest sp. z o.o., Centrum Medyczne ENEL-MED Capital Group has grown by another subsidiary. The Company will carry out operating activities in the sector of long-term medical care facilities, a project that the Issuer announced in their development strategy.

1.3. Management Board and Supervisory Board

The Management Board of Centrum Medyczne ENEL-MED S.A.



Adam Rozwadowski – President of the Management Board

Mr Rozwadowski has held the position of the President of the Management Board since 2006. A graduate of Gdańsk University of Technology. In the years 1972-1985, Mr Rozwadowski worked for STOEN as the manager of the general technical department and in the years 1985-1995 as the Director of the Office of Design and Implementation of Investments. Since 1993, Mr Rozwadowski has been managing Centrum Medyczne ENEL-MED, first as the General Director and later as the President of the Management Board. In addition, Mr Rozwadowski is the Deputy President of the National Association of Private Hospitals [*Ogólnopolskie Stowarzyszenie Szpitali Prywatnych*] and a member of the Management Board of the Polish Union of Private Healthcare Employers [*Ogólnopolski Związek Pracodawców Prywatnej Służby Zdrowia*].



Jacek Rozwadowski – Deputy President of the Management Board

Mr Rozwadowski has been performing the duties of the Deputy President of the Management Board since 2009. Mr Rozwadowski has been working for the company since 2002 and since 2008 he has held the position of Managing Director. Mr Rozwadowski is a graduate of the School of Business and Administration in Warsaw. Before joining the medical sector, he worked in the automotive industry. Between 1999 and 2002, he dealt with marketing and sales at DAF Trucks Polska Sp. z o.o. Before that, he worked for a year for DAF Trucks NV Holland where he was responsible for sales in Poland. In 1996–1998, he was a project manager at Elektrim S.A.

Until the publication day of this report the composition of the Management Board has remained unchanged.

Supervisory Board of Centrum Medyczne ENEL-MED S.A.


- • Anna Rozwadowska - Chairperson of the Supervisory Board
- • Anna Piszcz - Member of the Supervisory Board
- • Janusz Jakubowski - Member of the Supervisory Board
- • Zbigniew Okoński - Member of the Supervisory Board
- • Adam Ciuhak - Member of the Supervisory Board

Until the publication day of this report the composition of the Supervisory Board has remained unchanged.

1.4. Shareholding structure

As of the publishing date of this report, the shareholding structure was as follows:

Shareholder	Number of	% of capital	Number of votes	% of votes
Adam Stanisław Rozwadowski	7,124,000	30.23	7,124,000	30.23
Anna Maria Rozwadowska	7,123,950	30.23	7,123,950	30.23
Generali OFE (Open Pension	2,377,000	10.09	2,377,000	10.09
OFE PZU „Złota Jesień”	1,778,000	7.54	1,778,000	7.54
Jacek Jakub Rozwadowski	1,003,466	4.25	1,003,466	4.25
Bartosz Adam Rozwadowski	972,650	4.13	972,650	4.13
Other Shareholders	3,187,834	13.53	3,187,834	13.53



1.5. The activity of Centrum Medyczne ENEL-MED S.A. and its Capital Group

Centrum Medyczne ENEL-MED S.A. is a private operator of medical services in Poland that has been present on the Polish health care market since 1993.

The Company provides medical services in a total of 1402 facilities, including 22 of its own establishments, among which there are multi-profile clinics, two hospitals in Warsaw, an aesthetic medicine clinic ESTELL, and in-company clinics.

The multi-profile clinics and the aesthetic medicine facility are situated in attractive locations (for example in prestigious shopping centres or office blocks) in seven cities: Warsaw (Zacisze Hospital, the shopping centres of Atrium, Blue City, Arkadia, Puławska, Domaniewska, Centrum and aesthetic medicine clinic ESTELL in a Senator Building), Cracow (Galeria Krakowska Centre), Poznań (Kupiec Poznański Centre), Łódź (Manufaktura Centre), Gdańsk (Grunwaldzka Clinic in Office Island) and Wrocław (Arkady Wrocławskie Centre and the West Gate office block) and in Katowice (Silesia Business Park). In-company clinics, i.e. small branch clinics situated on our corporate clients' premises, offering a basic range of services only to the employees of a particular client, are located in Warsaw, Piła and Łódź. The only exception is the facility located in the Special Economic Zone, the Sub-Zone of Wrocław-Kobierzyce, which is used by the employees of companies belonging to the LG Cluster together with their families, as well as individual patients who are not employed in the companies with which ENEL-MED signed contracts for the provision of medical services.

Moreover, the Company operates two hospitals in Warsaw: the multi-specialisation 19-bed Zacisze Hospital and the 33-bed Centrum Hospital located at Al. Solidarności 128. In hospitals as well as in a multi-profile clinic in Gdańsk, ENEL-MED operates diagnostic centres equipped with MRI and CT devices (Centrum Hospital and Zacisze Hospital), as well as an MRI unit in Gdańsk.

The medical services provided by the Company include but are not limited to:

- primary and specialist outpatient care, including rehabilitation and ambulatory treatment
- dental health care
- imaging diagnostics (including tests performed using MRI, CT, USG, and X-ray)
- hospitalisation, including treatments and surgical procedures in selected specialisation areas, scheduled at Zacisze Hospital and Centrum Hospital
- off-site medicine and emergency home visits, as well as medical care in sudden cases
- aesthetic medicine, cosmetology, aesthetic gynaecology.

The Company's wide range of medical services is available both to patients who pay for each service provided and clients with prepaid medical care packages. Selected services can also be used under the National Health Fund. Furthermore, Centrum Medyczne ENEL-MED has signed medical service contracts with numerous insurance companies, such as Allianz, PZU Pomoc, Inter Polska, Signal Iduna, and Generali. The Company's settlements with insurance companies are effected on a fee-for-service basis.

2. MAJOR EVENTS OF THE 1ST HALF OF 2015

In the first half of 2015, the Company consistently pursued the published development strategy for the years 2014-2016, including the opening of new facilities and the continuation of work on the launch of the next ones. On 1 June, another branch clinic started operation in Wrocław, in the West Gate building, at ul. Lotnicza. The range of services provided includes those of GPs or internists, as well as dental services. The facility also offers ophthalmologic consultation, occupational medicine examinations and ECG monitoring.

Moreover, in the period presented, a multi-profile clinic in Katowice was being completed, the opening of which took place in the third quarter and the number of dental services was increased in line with the announced strategy. Currently, the Company has 46 dental centres in operation.

The first half of 2015 was also the time when a lease contract was concluded for the lease of space for another clinic in Warsaw, located in the area of Mokotów at ul. Postępu. The newly created facility (to open in the fourth quarter of 2015) will offer a wide range of procedures and consultations. The clinic will have an endoscopic lab. Additionally, patients here will be able to undergo a programme called "24 Hours For Your Health" intended to assess their general health within one day, whilst also testing for various lifestyle diseases.

In the period presented, the Company allocated PLN 2,356,690 of its profit for 2014 to pay dividends to its shareholders. This means that the pay-out for a single share amounts to PLN 0.10.

The first half of 2015 was also a period of continued growth in revenues. The Company reached PLN 114.5 million, which is 18%* more compared to the corresponding period of the previous year. In the first half of 2015 ENEL-MED generated a 19% increase in the area of prepaid medical packages, representing 69% in the revenue structure and a 22%* increase in commercial services, the development of which is key to the Company. It is also noteworthy that a significant increase in the margin at the EBITDA level was reached.

In the first half of 2014 the mean margin of EBITDA was 5.0%,* and in 2015 it has increased to 6.1%. Despite the depreciation growth of PLN 1 million the margin on gross profit level is also higher (1.1%* in the first half of 2014 and 1.3% in the first half of 2015).

There were no other significant events in the Capital Group except for those mentioned above.

* considering the sales of shares in the company which comprised 7 diagnostic facilities

3. OTHER INFORMATION

3.1. Principles of drawing up interim condensed financial statements

The parent company and Capital Group draw up their financial statements in accordance with International Accounting Standards (IAS). The functional and presentation currency is Polish zloty (PLN). The basis for the balance sheet valuation and the prepared statements is the assumption that both the parent company and its subsidiaries will continue their business activity.

Detailed principles and methods of drawing up interim consolidated financial statements are discussed in the Additional notes to the consolidated financial statements for the 1st half of 2015.

Detailed principles and methods of drawing up the interim separate financial statements were discussed in the Additional notes to the separate financial statements for the 1st half of 2015.

3.2. Basic threats and risks associated with the remaining months of the financial year

- **Risk arising from the deterioration of the financial situation of the Company's clients**

The sale of medical subscriptions targeting corporate clients constitutes a major source of the Company's revenue (69% of the revenue structure). There is a risk that if the financial situation of a given client deteriorates significantly, the client might desist from offering medical care to its employees, which might lead to the termination of the contract or reduction of the range of services thus affecting the Company's revenue. Another form of potential risk is the reduction of employment in the client's company, which may decrease the related revenue. The Company is currently dealing with nearly 3,000 enterprises and given such a considerable diversification the impact of the above mentioned risk on the revenue of the Company and the Capital Group is relatively insignificant.

- **Risk arising from becoming dependent on clients and distribution channels**

There is a risk that the share of a given client or a given distribution channel in the Company's revenues becomes so significant that the Issuer's financial results may deteriorate in the case of a loss of such a client or a decrease in the sales in a given channel. Given the above and in order to minimise the risk of becoming dependent on one particular client or one distribution channel, the Company constantly pursues the policy of diversifying its sources of revenue. The services are sold via long-term subscription contracts and insurance contracts (the Issuer cooperates with insurance companies, including PZU Pomoc, Allianz, Inter Polska, Signal Iduna and Generali). The Company has also signed a contract with the National Health Fund.

- **Risk of change in the contracting policy of the National Health Fund (NHF)**

The Company has signed many contracts with the NHF concerning hospitalisation and diagnostics. Each year the value of the contract for a given year is determined. There is always a risk of changes in the contracting policy of the NHF. Furthermore, it should be remembered that in the light of the forthcoming parliamentary elections, there is an increased risk of contracting policy changes, including the possibility of the NHF being liquidated (another entity would deal with contracting). The above factors might negatively affect related revenues, however it is worth stressing that the sales in the first half of 2015, based on NHF contracting, amounted to merely 4% of the Company's revenue, while the Issuer took a number of measures to intensify commercial sales of hospital services and diagnostics, thus not relying solely upon one payer in this area of activity.

- **Risk of medical malpractice in relation to the Company's patients**

ENEL-MED provides a wide range of medical services including medical consultations, diagnostic and laboratory tests, as well as surgery. As with every medical facility, there is a risk that the Company's medical personnel will commit an act of medical malpractice in relation to a patient. As a result of such an error, the Company may incur compensation costs, and this may seriously undermine the Company's reputation. In order to minimise this risk, the Issuer has implemented management and patient service procedures in such situations. A separate unit has been established in the Issuer's organisational structure responsible for the quality of medical services and for the compliance of medical processes with the standards and procedures. Additionally, both the Company and the physicians have taken out medical malpractice insurance policies in case of any malpractice.

- **Pandemic/epidemic risk**

The Company provides medical services to a wide range of patients in Poland. There is a risk that in the event of a pandemic or epidemic, the Issuer will be forced to provide services to a significantly larger number of patients, which may negatively influence the Company's financial performance and the effectiveness of its operations. In order to minimise the risk, ENEL-MED has developed relevant procedures and standards of conduct to be followed in case of the above-mentioned risk (the so-called pandemic plan), which were to some extent used in 2009 when facing the threat caused by the A/H1N1 virus. The main rules of the developed pandemic plan provide for preparing the method of dealing with patients which are suspected of having been infected, changing the department's work organisation, conducting the campaigns that promote pro-health behaviour and minimise the risk of infection, introducing quick diagnostic tests thanks to which viral infections may be differentiated and shortening the time spent on one visit during the period of the increased number of visits.

- **Risk associated with processing sensitive data**

Centrum Medyczne ENEL-MED provides complex medical services nationwide. Keeping patients' medical records means that the Company has access to particularly sensitive data. There is a risk that the unintentional disclosure of sensitive data may occur in the course of operating activities. In order to minimise the risk, the Issuer has developed and implemented a personal data protection policy. In their daily work, all employees and partners must strictly follow this policy. Moreover, each new employee is trained in personal data protection and has appropriate authorisation. Data protection policy functions as a procedure included in the quality management system certified for compliance with the ISO 9001:2008 standard. The correct process of safe personal data processing is constantly monitored by the Chief Information Security Administrator at the registered office of the Issuer, as well as by local Information Security Administrators who operate as the branch managers. Each and every employee and partner is obliged to report any information to the Administrator about suspected cases of non-compliance with the personal data protection policy. The role of the Information Security Administrator is to immediately analyse reasons of breaches and take measures aimed at avoiding similar situations in the future.

- **Risk of significant change in the macroeconomic situation in Poland**

The Company carries out its business activities on the national market of medical services. Therefore, the financial results achieved by the Issuer are indirectly connected with such macroeconomic factors as growth in GDP, unemployment rate, employment rate, dynamics of salary growth, inflation rate and interest rates. These factors indirectly influence the demand for medical services both among corporate and individual clients as well as insurance companies. They also influence the budget of the National Health Fund, which is the largest individual client of the Issuer (4% of the Company's sales revenue).

In March 2015, the Monetary Policy Council (MPC) lowered interest rates by 50 bps. Since then the reference rate has been 1.5%. This is the lowest level ever. Throughout 2014 and 2015, the inflation rate has been below the lower inflation bracket, dropping below zero in July 2014 (deflation). In February 2015 the Consumer Price Index (CPI) reached -1.6%, its lowest year-on-year level. The subsequent months saw a slight increase and in May 2015 CPI stood at -0.9% year-on-year. According to MPC, on a yearly basis, prices in the months to come will continue to fall due to substantial declines in the price of raw materials noted earlier. According to the report published by the National Bank of Poland (NBP) in July, the inflation rate will remain under the inflation target until the end of 2017. The target is 2.5% with possible deviations of +/- 1 per cent.

The beginning of the year saw a continuation of the dynamics of GDP growth. In the first quarter it increased by 3.6% year-on-year. According to the forecasts of MPC, the dynamics of GDP in the second quarter were close to that of the first three months. Such optimistic forecasts are shared by NBP, which estimates that the Polish economy will grow by 3.6% this year, 3.4% in 2016 and 3.6% in 2017. A better economic situation in Poland is mainly a consequence of the upturn of economy in the Euro zone, increased export to other markets and increased consumption as a result of more optimistic expectations of consumers with regard to their situation in the future as well as low interest rates. Growth is also noticeable in the area of entrepreneurial investments.

The Polish labour market is looking good too. The unemployment rate has been steadily decreasing since the beginning of 2014, and in May this year it reached 10.8%.

The influence of the anticipated changes in the GDP growth rate, unemployment and real wages and salaries should not have any significant impact on the Company's financial situation. It should be emphasized that the Company's revenue is mainly dependent on long-term contracts. Moreover, the Company's services are used by wealthy people who, as shown by the years 2012 and 2013, will be able to afford to maintain the current expenditure structure even in a time of a slower salary growth rate. The growth in real wages and salaries and the decrease in structural unemployment should have a beneficial effect on the Company's financial result in the long run.

It should be emphasised that recent months have brought about an increased political risk connected with the unfavourable development of the international situation. The recent events in Ukraine, exacerbated relations between Russia and Ukraine and consequently relations between Russia and the Western world may have a significant impact not only on the Polish economy but also on financial markets. Additionally, the unstable economic and political situation in Greece should be taken into consideration. While the risk of this country exiting the Euro zone has been averted, the economic situation of Greece is far from ideal. Changes in the Polish political scene are not without significance. It is uncertain how foreign investors will react to a potential change of the ruling party that may occur after the parliamentary election this autumn. A possible escalation of the issues mentioned above may lead to a weakening of the Polish currency, drops in the stock exchange, or an increase in the profitability of treasury bonds. However, upon writing this report, it is difficult to assess the probability of different scenarios for the political situation.

- **Risk of significant foreign exchange fluctuations**

Foreign exchange fluctuations affect the Company's operating activities because of rent payments (which in most cases are denominated in EUR) and the purchase of medical equipment (whose price is typically denominated in EUR). Rent payments are made in PLN at the exchange rate of the National Bank of Poland. If there are significant deviations from the actual exchange rate in comparison to the assumed level, the Issuer may record a gain or loss on account of differences in foreign currency exchange rates. The Company constantly monitors changes in foreign exchange rates. The Issuer does not hedge foreign exchange risk by means of derivatives. In order to minimise the influence of foreign exchange rates fluctuations on the financial results of the Company, the Management Board regularly monitors the market rental rates taking into account the current foreign exchange rates.

It should be stressed that the majority of forecasts expect quite a considerable variability of PLN exchange rate in connection with the situation beyond the Polish eastern border and in Greece. Long term, the value of Polish currency is expected to increase.

- **Risk of significant changes in interest rates**

The Company finances its activities using external funds, including credits and loans and purchases medical equipment under finance leases. The finance charges related to servicing external financing are directly dependent on the level of the WIBOR rate. If the level of interest rates changes, the Company's financial results may be different from those assumed. At the end of 2012, the Monetary Policy Council started a period of reductions in interest rates. Following the latest reduction that took place in March this year, the reference rate stands at 1.5%. At this point, it is expected that current interest rates should be maintained in the months to come. The analysts have been making such conclusions on the basis of, e.g., recent projections of the inflation rate prepared by NBP and opinions of the MPC members. The Company manages financial liabilities in a way that allows for the minimisation of financial costs related to debt service. Thanks to lengthy cooperation with financial institutions, it negotiates advantageous interest rates. The Management Board is constantly monitoring the situation in the banking sector and if new possibilities of external financing arise, the Company renegotiates the existing credit agreements in order to improve their terms and conditions. The risk of changes in interest rates is reduced also by making investments using uncommitted cash in fixed-term deposits. The Issuer does not hedge the interest rate risk by means of derivatives.

- **Credit risk**

The Company is not subject to excessive risk due to the concentration of credit sales. The Issuer enters into transactions exclusively with renowned companies with sound credit standing. All the clients who wish to take advantage of a buyer's credit undergo preliminary verification. Moreover, owing to the regular monitoring of the receivables, the Company incurs minimal risk of unrecoverable receivables.

In selling to natural persons, the Company accepts cash or pre-payment. With regard to other financial assets of the Company, such as cash or cash equivalents, or financial assets available for sale, credit risk arises when the other contracting party is unable to pay. With regard to financial obligations, the credit risk may result from the Company's inability to fulfil the conditions stipulated in credit contracts. In principle, it consists of partial non-performance of the contractual level of indebtedness, which may result in an increased margin, a request for additional surety or a repair programme, or in extreme cases the termination of the credit contract by the Bank. With a view to minimising such a risk, the Company is constantly monitoring crucial figures and if the situation deteriorates, it undertakes negotiations with the creditor. There are no significant concentrations of credit risk in the Company.

- **Liquidity risk**

The Issuer's liquidity risk management involves the constant monitoring and planning of cash flow in the Company in order to ensure an adequate level of financial assets necessary for day-to-day operations.

The Issuer monitors the risk of insufficient funds using a tool for periodic liquidity planning. This tool considers maturity dates, both for investments and financial assets (e.g. accounts receivables, other financial assets) and expected cash flow from operating activities. Surplus cash is deposited in banks in such a way that the maturity dates do not adversely affect the day-to-day business of the Company. The Issuer's goal is to maintain a balance between continuity and flexibility of financing by using diverse sources of funds, such as overdrafts, bank loans, financial lease agreements and hire-purchase contracts.

- **Risk of changes in legal regulations and their interpretations**

The changes introduced or planned to be introduced to provisions of law, in particular to commercial, tax and labour law, may constitute a risk factor leading to negative consequences for the Company. Similar consequences bring about changes in the interpretation of binding laws, in particular in relation to tax law regulations. The Company's activity is also indirectly influenced by regulations concerning the public health care sector, including those regulations that define the methods and rules of its financing, as well as defining the scope in which commercial patients may be admitted to public sector facilities. Depending on the nature of the changes introduced, they may have a positive or a negative effect on the activity of the Group and other entities in the sector.

- **Risk of more intense domestic and foreign competition in the market**

Investors recognize the attractiveness of the Polish market of private medical services, as well as good perspectives for further development in this sector. The aforementioned may result in an increase in competition amongst Polish and foreign enterprises which may be observed in recent transactions on the Polish medical services market. ENEL-MED has been operating in a competitive environment for many years whilst being able to maintain high sales dynamics at all times.

3.3. THE MANAGEMENT BOARD'S POSITION ON THE FEASIBILITY OF THE PREVIOUSLY PUBLISHED FORECASTS FOR THE YEAR

The Company did not publish any forecasts of financial results for the year 2015.

3.4. Information on shareholders holding at least 5% of the total number of votes at the GM directly or indirectly through subsidiaries

The table below presents the shareholders who hold at least 5% of the total votes at the general meeting of shareholders of the Issuer as of the publication date of this interim report.

Shareholder	Number of shares	% of capital	Number of votes	% of votes
Adam Stanisław Rozwadowski*	7,124,000	30.23	7,124,000	30.23
Anna Maria Rozwadowska*	7,123,950	30.23	7,123,950	30.23
Generali OFE	2,377,000	10.09	2,377,000	10.09
PZU "Złota Jesień" Open Pension Fund	1,778,000	7.54	1,778,000	7.54

* there is a presumed agreement between Adam Stanisław Rozwadowski and Anna Maria Rozwadowska (along with the family members, Jacek Jakub Rozwadowski and Bartosz Adam Rozwadowski, they hold 16,224,066 shares authorising them to cast 16,224,066 votes at the GM of shareholders).

Since the submission of the previous report (for the first quarter of 2015), the Company has received a list of shareholders nominated to take part in the GM from the National Depository for Securities that implies that PZU "Złota Jesień" Open Pension Fund has increased the number of shares and votes at the GM of the Issuer. As of the publication day of the report for the first quarter of 2015 this fund held 1,668,000 shares and votes at the GM of shareholders, which constituted 7.13% of the shares and votes, and currently it holds 1,778,000 shares and votes, which constitutes 7.54% of the Issuer's shares and votes at the GM of shareholders of the Company.

3.5. Information on the Issuer's shares held by members of the management and supervisory authorities

The Issuer's shares held by members of the Management Board and Supervisory Board as of the day of submitting this report are presented in the table below.

Shareholder	Number of shares	% of capital	Number of votes	% of votes
Adam Stanisław Rozwadowski*	7,124,000	30.23	7,124,000	30.23
Anna Maria Rozwadowska*	7,123,950	30.23	7,123,950	30.23
Jacek Jakub Rozwadowski*	1,003,466	4.25	1,003,466	4.25

* there is a presumed agreement between Adam Stanisław Rozwadowski and Anna Maria Rozwadowska (along with the family members, Jacek Jakub Rozwadowski and Bartosz Adam Rozwadowski, they hold 16,224,066 shares authorising them to cast 16,224,066 votes at the GM).

The ownership structure of shares held by the managers and supervisors has changed since the publication of the previous periodic report - the report for the first quarter of 2015. Pursuant to the notices that were registered at the Company, Jacek Jakub Rozwadowski, who holds the position of the Deputy President of the Management Board, has acquired 5,619 shares in the Company.

3.6. Information on pending proceedings before courts, arbitration bodies or public administration bodies with regard to liabilities or receivables

As of the publication date of the interim report neither the Company nor the Capital Group were a party to any proceedings held before any court, arbitration body or public administration body with regard to receivables in the amount equal to at least 10% of the Issuer's equity.

However, in the first quarter of 2015 an application was filed with the District Court for Warszawa-Śródmieście (First Civil Division) in Warsaw to summon the Issuer to a conciliation hearing in order to reach an amicable settlement as a result of which the Company would commit itself to pay to the applicant, Agnieszka Koncka, the amount of PLN 10,000,000.00 as compensation for damage, the amount of PLN 1,000,000.00 as compensation and disability pension in the amount of PLN 20,000.00 per month. The total value of the dispute was estimated at PLN 11,240,000.00. As the basis for these claims, the applicant indicates incorrect treatment that was only to some extent was conducted in the Company's hospital. According to the Management Board of the Company the applicant's claims are unjustified both in principle and as to the amount claimed. Notwithstanding the foregoing, the Management Board states that the claims put forward by the applicant are covered by the insurance agreement concluded by the Company with Powszechny Zakład Ubezpieczeń Spółka Akcyjna (PZU S.A.). The information held by the Management Board provides also that the claims resulting from the treatment of the applicant in the hospital of the Company have been previously reported by the applicant to the Company's insurer in a much lower amount (PLN 150,000.00 as compensation, PLN 150,000.00 as compensation for damage and the amount of PLN 4,500.00 as compensatory pension per month). The insurer, following liquidation procedure, did not find any characteristics of medical malpractice or failure to exercise due care in the treatment of the applicant. In particular, the evidence collected at the time indicated that the medical services provided to the applicant in the Company's facility were compliant with the current state of medical knowledge and using the available methods and means, therefore the Management Board is of the opinion that the Company is not to be held responsible. In view of the fact that in the session appointed to reach a settlement the parties did not achieve one, the proceedings were discontinued as of 6 May 2015.

As of the publication date of this report, neither the Company nor the Capital Group took part in any proceedings concerning receivables the total number of which constitutes at least 10% of the Company's equity.

As of the publication day of the interim report, the value of liabilities in all pending proceedings did not exceed 10% of the Issuer's equity.

3.7. Information on the Issuer or its subsidiary granting a surety for credits or loans, or granting a guarantee if their total value is equal to at least 10% of the Issuer's equity

Neither the Company nor its subsidiaries granted any sureties for credits or loans or granted any guarantees to another entity to the value of at least 10% of the Issuer's equity.

3.8. Information on entering by the Issuer or its subsidiary into one or more transactions with related-parties if individually or jointly they are significant and have been concluded pursuant to other terms and conditions than market term and conditions

Neither the Issuer nor its subsidiaries concluded transactions with related undertakings on non-arm's length conditions.

3.9. Information on factors that, in the company's view, will affect its results in the perspective of at least the next quarter

In the first half of 2015 the amount and the interest rate on the investment loan with Bank Millennium S.A. was lowered. The current account overdraft is used minimally as a result of a substantial improvement in the financial results and the Company's financial management. These factors will lead to a further decrease in interest charges of Centrum Medyczne ENEL-MED S.A. and result in a drop in financial costs which have a direct influence on the Company's profit.

Intensified investment activities that the Company is pursuing now as part of the investment plan announced in the development strategy for the years 2014-2016, e.g. the opening of two new facilities in Katowice, another clinic in Wrocław, a sports medicine clinic on the premises of Legia Warszawa Football Club, and the creation of more clinics in selected locations are intended to substantially increase the operating potential of the Company. In the first half of the year, two facilities have already been opened - in Wrocław and in Katowice. More are scheduled to open in the second half of 2015 - another in Katowice featuring a modern MRI, and two in Warsaw - a facility offering pre-paid services and endoscopic examination, and a sports medicine clinic.

3.10. Other information which could significantly affect the evaluation of assets, financial condition and financial result of the Issuer

The Company concluded agreements for space lease for multi-profile clinics in the Mokotów Plaza office block located at ul. Postępu in Warsaw. The agreements were concluded for a period of 10 years, and the cost of the lease as well as operating costs will amount to approx. PLN 5,813,379.01 net during the term of the agreements.

3.11 Other information which in the Issuer's opinion is important for the evaluation of its personnel, assets and financial condition, financial result and changes therein, as well as information important for evaluation of the Issuer's capacity for performing the obligations

The Company is systematically increasing its potential in diagnostic imaging. On 30 June 2014 the Company signed an agreement with GE Medical System Polska sp. z o.o. for the purchase of 4 MRI systems and 12 USG cameras. The Contract value amounts to PLN 17,618,900.00 gross. The first magnetic resonance apparatus Optima MR 360 Advance 1.5T was started up in mid-September 2014 in Zaczysze Diagnostic Hospital in Warsaw. The remaining three magnetic resonance systems Gold Seal Signa HDxt 3.0T will be available at the end of 2015 at new multi-profile facilities of ENEL-MED, located in Katowice and Warsaw. Magnetic resonance imaging is cutting-edge technology that provides very accurate images of the interior of the human body. Seeing in greater detail, doctors are able to make an accurate diagnosis at a much

earlier stage of disease development. This consequently allows doctors to apply the most optimal and effective treatment. New MRI systems perform tests in half the time needed by apparatus from earlier generations. Thanks to this a greater number of patients can be examined each day. New magnets (1.5T / 3T), specialised diagnostic coils and the innovative software installed, greatly extend the scope of clinical applications and enable the operator to diagnose an even larger group of patients than ever before. The Company also bought 12 modern ultrasound cameras (Voluson S6, Voluson E6) for all the multi-profile centres of ENEL-MED.

Added to that, the Issuer concluded the following annexes with Bank Millenium S.A.: annex to the multi-product contract based on which the Bank grants the Company a global limit in the amount of PLN 15,000,000.00 for the period lasting until 24 April 2016, and annex to the mortgage contract based on which the Bank grants the Company a credit in the amount PLN 10,000,000 for the period lasting until 24 May 2019 to finance current operations.

Adam Rozwadowski
President of the Management Board

Jacek Rozwadowski
Deputy President of the Management Board